Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. American journal of hematology Medeiros, B. C., Chan, S. M., Daver, N. G., Jonas, B. A., Pollyea, D. A. 2019


Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post-remission therapy, and identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Emerging data suggest that targeted post-remission therapy, alone or in combination with chemotherapy, may improve outcomes, and results of ongoing clinical trials will further define potential clinical benefits. This article is protected by copyright. All rights reserved.

View details for PubMedID 30945331